Dose specification in External Beam Radiotherapy for CyberKnife and VMAT techniques applied to a case of prostate cancer by Ślosarek, Krzysztof et al.
375
Irradiation techniques
NOWOTWORY Journal of Oncology
2016, volume 66, number 5, 375–380 
DOI: 10.5603/NJO.2016.0067 
© Polskie Towarzystwo Onkologiczne
ISSN 0029–540X
www.nowotwory.edu.pl
1Radiotherapy Planning Department, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology  
Gliwice Branch, Poland
2Humanitas University, Sosnowiec, Poland
3Department of Radiotherapy, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology  
Gliwice Branch, Poland
Dose specification in External Beam Radiotherapy for CyberKnife  
and VMAT techniques applied to a case of prostate cancer
Krzysztof Ślosarek1, 2, Joanna Kopczyńska1, Wojciech Osewski3
Recent technological development in radiotherapy allows to introduce new irradiation techniques implemented on 
the conventional accelerators and on the machines such as CyberKnife (CK). These significantly changes the philoso-
phy of planning and execution of radiotherapy. One of the fundamental concepts in radiotherapy is to define the 
therapeutic dose. It can be defined in the point, at the selected isodose, as an average value, or combined with the 
volume. We present the case of prostate cancer patient irradiated using CK machine and classic accelerator (VMAT). 
The differences in dose distribution and its value are shown. The analysis indicates that the average dose in Planning 
Treatment Volume (PTV) is a useful parameter during comparison of the dose distributions realized on machines of 
different type.
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Aim
To choose those prescribed dose values that enable the 
same bioequivalent dose to be administered when using 
two different radiation techniques.
Background
Extra cranial stereotactic radiotherapy is now rendered 
possible by rapid technological developments when two-
dimensional (2D) treatment planning became converted 
to three-dimensions (3D), followed by the introduction 
of Intensity Modulated Radiotherapy (IMRT), Volumetric 
Modulated Arc Therapy (VMAT) and CyberKnife (Accuray, 
Sunnyvale, CA, USA) [1–3]. The therapeutic dose is one 
of the basic concepts in radiotherapy. Modern irradiation 
techniques have now enabled the dose to be escalated to 
the PTV (Planned Treatment Volume) whilst simultaneously 
protecting/sparing OaRs (Organs at Risk) [4]. Nevertheless, 
knowing the fractional or total dose for a given field is in-
sufficient, because they can be defined in different ways: as 
a point, by a selected isodose, ‘X’ percent of the prescribed 
dose coverage [5], ‘Y’ percent of the treated volume or the 
mean, modal or median dose to the PTV. 
Dose distributions generated by modern therapeutic 
instrumentation are intentionally inhomogeneous and 
are now different to those previously accepted [6–9]. For 
example, the concept of isocenter, by which means the 
dose is commonly defined, is absent for the CyberKnife 
(CK) instrument. For classical accelerators, using IMRT and 
VMAT dynamic techniques, the shape of the beam changes 
during exposition. It is therefore reasonable to define doses 
in volumes, but not at a point because this can become 
obscured by the moving collimator leaves. Usually, the ir-
radiation is performed on only one type of therapeutic 
instrument. In some cases however, treatment is required 
to be continued on through using a different instrument, 
where information concerning the absorbed dose and the 
delivery location becomes important [5]. Dose distributions 
obtained using CK instruments definitely differ from those 
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used for the IMRT and VMAT dynamic techniques. For the 
CK, doses are defined to isodoses (ranging 70–90%) whereas 
for conventional accelerators in dynamic techniques they 
are defined by the volume (95% of the prescribed dose at 
100% of treated volume) [10–12].
Material and methods
This article presents the case of an irradiated patient with 
prostate cancer that underwent CK treatment. A total treat-
ment dose of 36.25 Gy was given as five fractions (7.25 Gy) 
defined to the 85% isodose [13] and had been planned us-
ing the MultiPlan v. 4.1 (Accuray, Sunnyvale, CA, USA). The 
overall treatment time was 10 days. Organs at Risk: bladder, 
rectum and femoral heads, those volumes were reduced by 
the common part with PTV. 
According to treatment protocols,13 planned doses 
to the bladder cannot exceed: V18Gy — 55%, V29Gy — 25%, 
V32,6Gy — 15% and V23,25Gy — 10%, for the bladder these 
being: V18Gy — 55%, V29Gy — 20%, V32,6Gy — 10% and V23,25Gy 
— 5% for the rectum: V25Gy — 45% and for the femoral heads 
the maximum dose cannot exceed 120% of the prescribed 
dose. 
Stereotactic radiotherapy for prostate cancer can also 
be delivered by the VMAT technique using classical ac-
celerators [14], where the dose distribution is calculated 
by the Eclipse TPS v. 10 (Varian Medical Systems, Palo Alto, 
CA, USA). A dose fraction of 7.25 Gy was defined as 95% of 
the prescribed dose to 100% of the treated volume. Dose 
limits to the OaRs were kept to the same level as for the 
CyberKnife technique. 
Comparisons of dose distribution were performed on 
the Eclipse TPS. In-house ‘DDcon’ software was used for 
exporting the CK dose distribution from the Multiplan TPS 
to the Eclipse TPS [15]. In order to assess the differences 
between doses to the CTV (Clinical Target Volume) and PTV, 
in the form of dose sets for both techniques, the exported 
differential DVH files were compared by the t-test for inde-
pendent samples using STATISTICA v. 10 software; statistical 
significance being taken as ≤ 0.05. In-house RPIWin software 
was also used to calculate the RPI coefficient [16] for deter-
mining the differences in dose distribution between both 
techniques; this being achieved by using cumulative DVH’s 
for both techniques. Finally, bioequivalent doses (Diso2Gy) 
were calculated for both treatment methods, and based on 
the mean dose they were normalised to the 2Gy fraction 
using a linear-quadratic model (LQ). Bioequivalent doses 
directly affect the TCP.
Results
Figure 1 shows the calculated CK dose distribution ac-
cording to the previously described scheme along with the 
Dose Volume Histograms (DVH) for the CTV, PTV, rectum, 
bladder and femoral heads structures. This treatment plan 
was accepted and performed on the CK. 
Figure 2 shows the calculated dose distribution for the 
same patient, but using the VMAT technique with classical 
Figure 1. Planned dose distribution for the CyberKnife. Plane A — transversal, B — frontal and C — sagittal together with D — DVH. The total 
36.25 Gy dose was defined at the 85% isodose. Blue indicates a dose of 5 Gy and red of 41 Gy
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accelerators (Linac CL23EX Varian Medical Systems, Palo 
Alto, CA, USA). The treatment plan consisted of 3 arcs and 
20 MV beams. The dose was defined at 95% of the planned 
dose in 100% of the irradiated volume. 
After analysing dose distributions for both DVH-based 
treatment plans, the mean, median, modal, minimum and 
maximum dose values demonstrated considerable variation; 
as shown in Table I. 
The planned total dose (36.5 Gy) leads to delivering 
a maximum dose of 43 Gy to the CTV for the CK and 39 Gy 
for the VMAT techniques. These differences are especially 
pronounced in the differential histogram. The mean doses 
to the CTV and for the CK and VMAT techniques were re-
spectively 39.9 Gy and 36.2 Gy, whilst those for the PTV 
were respectively 40.6 Gy and 35.8 Gy. The data are shown 
in Figure 3.
Upon analysing simultaneous doses to critical organs, 
differences between the CK and VMAT method are small; 
as shown in Figure 4.
Significant statistical differences were found between 
doses to the CTV (p = 0.0002, t-test for independent samples) 
and to the PTV (p = 0.0262), when comparing the dose distribu-
tions for CK (dose defined at the 85% isodose) with those for the 
VMAT (95% of planned dose to 100% of the CTV volume). The 
minimum, maximum and mean values are presented in Table I. 
Correspondingly, there were no significant differences for the 
bladder (p = 0.9344), rectum (p = 0.2027) nor in the femoral 
heads; right (p = 0.3036) and left (p = 0.5252).
Table I. Total doses; minimum, maximum and mean for CK and VMAT treatment techniques. Therapeutic doses were defined according to recommendations 
for both methods as: 85% of the dose to the CTV for CK and 95% of the dose to 100% of the CTV for VMAT. Bold indicates values that require to be taken 
into account when evaluating the treatment plan
Total dose [Gy]
Minimum Maximum Mean
CK VMAT CK VMAT CK VMAT
CTV 35.2 34.4 42.5 37.5 39.9 36.2
PTV 34.2 31.1 44 37.5 40.6 35.8
Rectum 1.5 0.6 39.3 35.7 14.6 14.3
Bladder 2.5 1.1 36.9 35.4 19.5 12.9
Femoral head — left 0.6 0.4 14 13.1 6.2 5.7
Femoral head — right 1 0.5 13.7 14.2 6.1 6.9
Figure 2. Planned dose distribution for the VMAT technique. Plane A — transversal, B — frontal and C — sagittal together with D — DVH. The total 
dose 36.25 Gy was defined at the 95% isodose which covers 100% of the CTV. Blue indicates a dose of 5 Gy and red of 41 Gy
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Figure 3. Differential DVHs for the CK and VMAT irradiation techniques for a planned dose of 36.25 Gy: A — for the CTV and B — for the PTV;  
the mean dose for the CK technique being greater than for VMAT as on the graph
Figure 4. Dose distribution obtained by the CK and VMAT techniques for Organs at Risk: A — bladder, B — rectum, C — left femoral head and  
D — right femoral head
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The calculated RPI coefficient for the CK was 0.5095 and 
0.5443 for the VMAT meaning that the treatment plan using 
the latter technique better met our expectations. Neverthe-
less, it can be said that the dose distributions calculated 
for both methods are comparable from the viewpoint of 
treatment planning.
According to the LQ model, the calculated bioequivalent 
dose (to a 2 Gy fractional dose) for CK and VMAT are however 
different, being respectively 99.6 Gy2 vs 83.6 Gy2 for the CTV 
and 102.7 Gy2 vs 82.0 Gy2 for the PTV.
It should also be emphasised, that the doses recorded 
in the treatment cards were 36.25 Gy for both CK and the 
classical accelerator.
In order to make dose distributions comparable be-
tween irradiation techniques for the CTV and PTV, along 
with the delivered bioequivalent doses, a mean dose value 
of 39.9 Gy to the CTV was chosen for the CK technique. 
A re-normalisation thus became necessary for the VMAT 
technique, such that its value was equal to the mean CK 
dose, as shown in Figure 5.
Table II compares the minimum, maximum and mean 
doses for both techniques where the VMAT doses were re-
normalised to CK mean dose. Red denotes values requiring 
to be taken into account when evaluating the treatment plan.
Re-normalised dose values were likewise calculated to al-
low the comparison of dose distributions between methods 
Table II. Total doses, minimum, maximum and mean values for the CK and VMAT techniques, where the mean doses for VMAT were normalised to the 
mean CK value. Bold denotes values that require special attention when evaluating the treatment plan
  Total dose DGy2 (Gy2)
Minimum Maximum Mean
α/β [Gy] CK VMAT CK VMAT CK VMAT
CTV 1.5 85.9 82.4 121.4 96.4 108.1 90.4
PTV 2 75.6 63.9 118.8 89.1 102.7 82.0
Rectum 15 1.4 0.5 52.8 46.5 15.4 15.0
Bladder 15 2.3 1.0 48.6 46.0 21.7 13.3
Femoral head — left 15 0.5 0.4 14.7 13.6 5.9 5.4
Femoral head — right 15 0.9 0.4 14.3 14.9 5.8 6.6
Figure 5. Differential DVH’s for CK and VMAT technique; A — CTV, B — PTV, C — bladder, D — rectum, E — right femoral head, F — left femoral head
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(100% = mean dose). No significant differences were found 
for the CTV (p = 0.53330), PTV (p = 0.612088) nor for the OaRs 
(Bladder, Rectum , Femoral Heads; p = 0.075). The calculated 
RPI factor for the VMAT was 0.5673, thereby indicating that 
the relationship between the dose to the CTV/PTV and 
OaRs is improved in terms of the assumptions made to dose 
distribution. The calculated Bioequivalent Doses, (based on 
the LQ model), to the CTV/PTV were 99.6/102.7 Gy2 and 
99.6/97.8 Gy2 for CK and VMAT, respectively.
Conclusions
Upon comparing dose distributions between two dif-
ferent irradiation methods, the bioequivalent doses may be 
different irrespective of whether the therapeutic dose and 
the fractionation method have been declared the same. The 
mean dose value should therefore be taken into account 
for the therapeutic dose. This is of course does not accord 
with the reported recommendations, nevertheless such 
information could prove valuable when comparing different 
irradiation techniques. 
For the presented case, the fractional dose for the VMAT 
technique should be increased from 7.25 to 7.99 Gy thus 
making the bioequivalent doses comparable for the two 
studied methods. The described situation provides an ex-
ample which not only applies to different therapeutic instru-
ments, but also to different irradiation techniques used on 
the same accelerator e.g. CRT vs IMRT/VMAT.
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